Key messages from scientific research that's ready to be acted on
Got It, Hide thisCrandall CJ, Newberry SJ, Diamant A, et al. Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: An Updated Systematic Review. Ann Intern Med. 2014;161:711-23.
In people with osteoporosis, do drugs prevent fractures (bone breaks)? Are some drugs better than others? What are the side-effects of drugs?
Osteoporosis weakens your bones and makes them more likely to fracture, often at the hip, spine, or wrist. Anyone can get osteoporosis. Drugs may prevent fractures, although they also have side-effects.
The researchers did a systematic review, searching for studies that were published in English up to March 2014.
They found 294 studies, including systematic reviews, randomized controlled trials, and nonrandomized studies.
The key features of the randomized trials were:
Compared with placebo:
There wasn’t enough information to determine if some drugs were better than others.
The drugs had different side-effects.
In women with osteoporosis, alendronate, risedronate, zoledronic acid, denosumab, and teriparatide reduce spinal and non-spinal fractures, and ibandronate and raloxifene reduce spinal fractures. The drugs have different side-effects. In men, zoledronic acid reduced spinal fractures.
Outcomes | Drugs | Comparison | Absolute effect of drugs | Strength of evidence* |
Spinal fractures in women | Alendronate, ibandronate, risedronate, zoledronic acid, denosumab, teriparatide, raloxifene | Placebo | About 11 to 17 fewer women out of 1,000 had spinal fractures | Strong |
Non-spinal fractures in women | Alendronate, risedronate, zoledronic acid, denosumab, teriparatide | Placebo | About 15 to 20 fewer women out of 1,000 had non-spinal fractures | Strong |
| Raloxifene | Placebo | No effect | Not reported |
Spinal fractures in men | Zoledronic acid | Placebo | About 33 fewer men out of 1,000 had spinal fractures | Moderate – just 1 study |
SIDE-EFFECTS |
|
|
|
|
Mild upper-gastrointestinal symptoms | Bisphosphonates, denosumab, teriparatide | Not reported | About 72 to 956 events in 1,000 people | Strong |
Atypical fracture of the thigh bone | Bisphosphonates | Not reported | About 2 to 100 events in 100,000 women | Low |
Osteonecrosis (loss) of the bone of the jaw | Bisphosphonates | Not reported | Fewer than 1 to about 43 people out of 1,000 had events | Low |
Influenza-like symptoms | Zoledronic acid | Not reported | About 728 to 896 events in 1,000 people | Strong |
Hypocalcemia (low calcium levels in blood) | Zoledronic acid | Not reported | About 5 to 118 events in 1,000 people | Strong |
Infection | Denosumab | Not reported | About 8 more people out of 1,000 had infections | Moderate |
Hypercalcemia (high calcium levels in blood) | Teriparatide | Not reported | About 537 to 820 events in 1,000 people | Strong |
Headache | Teriparatide | Not reported | About 511 to 679 events in 1,000 people | Strong |
Hot flashes or thromboembolic events | Raloxifene | Not reported | About 24 to 35 events in 1,000 people | Strong |